RIPK3 is a key member of the receptor-interacting protein kinase (RIPK) family, involved in necroptosis, a regulated form of cell death. It plays a crucial role in necroptosis by interacting with RIPK1 to form necrosomes, which trigger caspase-independent programmed necrosis. RIPK3 is also involved in various diseases, including infections, inflammatory diseases, and tumors, by regulating autophagy, cell proliferation, and cytokine production. Recent research highlights the potential of RIPK3 as a therapeutic target for disease treatment. RIPK3 is involved in the release of inflammatory factors and has non-classical functions such as inducing inflammasome activation, ROS production, and autophagy regulation. It is associated with the pathogenesis of various cancers, showing both tumor-promoting and -suppressive activities. RIPK3's role in necroptosis is essential for immune responses, and its regulation is critical for disease progression. The RIPK3 signaling pathway is involved in various diseases, including ischemic injury, chronic inflammation, neurodegenerative diseases, and cancer. RIPK3 can be targeted to develop novel therapeutic strategies for these conditions. In cancer, RIPK3 has contradictory effects, as it can both inhibit and promote tumor growth depending on the type and stage of cancer. RIPK3-mediated necroptosis can inhibit tumor development through anti-tumor immunity but can also create an immunosuppressive environment that promotes tumor growth. RIPK3 is involved in various diseases, including neurodegenerative disorders, and its regulation is essential for maintaining cellular homeostasis. Overall, understanding the mechanisms and functions of RIPK3 is crucial for developing new therapeutic strategies for various diseases.RIPK3 is a key member of the receptor-interacting protein kinase (RIPK) family, involved in necroptosis, a regulated form of cell death. It plays a crucial role in necroptosis by interacting with RIPK1 to form necrosomes, which trigger caspase-independent programmed necrosis. RIPK3 is also involved in various diseases, including infections, inflammatory diseases, and tumors, by regulating autophagy, cell proliferation, and cytokine production. Recent research highlights the potential of RIPK3 as a therapeutic target for disease treatment. RIPK3 is involved in the release of inflammatory factors and has non-classical functions such as inducing inflammasome activation, ROS production, and autophagy regulation. It is associated with the pathogenesis of various cancers, showing both tumor-promoting and -suppressive activities. RIPK3's role in necroptosis is essential for immune responses, and its regulation is critical for disease progression. The RIPK3 signaling pathway is involved in various diseases, including ischemic injury, chronic inflammation, neurodegenerative diseases, and cancer. RIPK3 can be targeted to develop novel therapeutic strategies for these conditions. In cancer, RIPK3 has contradictory effects, as it can both inhibit and promote tumor growth depending on the type and stage of cancer. RIPK3-mediated necroptosis can inhibit tumor development through anti-tumor immunity but can also create an immunosuppressive environment that promotes tumor growth. RIPK3 is involved in various diseases, including neurodegenerative disorders, and its regulation is essential for maintaining cellular homeostasis. Overall, understanding the mechanisms and functions of RIPK3 is crucial for developing new therapeutic strategies for various diseases.